Skip to main content

Clinical Trials Using Universal Donor Expanded TGF-beta-imprinted NK Cells

Review the clinical trials studying universal donor expanded tgf-beta-imprinted nk cells on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-8 of 8

Donor NK Cell Therapy in Combination with Gemcitabine and Docetaxel for the Treatment of Relapsed or Refractory Sarcomas, The TINKS Trial
Status: Active
Location: 20 locations
Donor Immune Cells (Ex Vivo Expanded Natural Killer Cells) for the Treatment of Recurrent or Progressive Malignant Brain Tumors in Children and Young Adults
Status: Active
Location: 8 locations
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Status: Active
Location: 2 locations
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) cells with or without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
TGFbeta-imprinted Natural Killer Cells in Combination with Irinotecan, Temozolomide, and Dinutuximab for the Treatment of Patients with Relapsed or Refractory Neuroblastoma, Allo-STING Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Donor Immune Cells (TGFBi NK cells) for the Treatment of Recurrent, Progressive or Refractory Malignant Brain Tumors in Children and Young Adults
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio